Timing of Mammogram After Completing Trastuzumab
Patients should have their first mammogram 6 to 12 months after completing radiation therapy (if applicable), then continue annual mammography surveillance thereafter. 1
Surveillance Schedule
For patients who completed 52 weeks of adjuvant trastuzumab therapy for HER2-positive breast cancer:
- First post-treatment mammogram: 6-12 months after completing radiation therapy (if breast-conserving surgery was performed) 1
- Subsequent mammograms: Annually for life 2, 1
The NCCN guidelines explicitly state that "patients should wait 6 to 12 months after the completion of RT to begin their annual mammogram surveillance" and that "studies indicate that annual mammograms are the appropriate frequency for surveillance of patients with breast cancer who have had BCS and RT with no clear advantage to shorter interval imaging." 1
Key Considerations
If the patient had mastectomy (no radiation to breast tissue):
- Begin annual mammography of the contralateral breast immediately after treatment completion 2
- Continue annually as long as the patient remains in good health 2
If suspicious findings develop:
- Shorter interval imaging may be warranted based on clinical examination or imaging findings 1
- Do not wait for the scheduled annual mammogram if new symptoms arise 3
Important Caveats
The timing recommendation of 6-12 months post-radiation is critical because:
- Earlier mammography may show post-treatment changes that are difficult to interpret
- Research demonstrates that mammography yield during the first year after breast-conserving therapy is not greater than in the general screening population (1.9 cancers per 1,000 breasts) 4
- The second year shows slightly higher yield (4.9 per 1,000 breasts), supporting annual surveillance thereafter 4
Do not perform routine screening for distant metastases in asymptomatic patients—there is no indication for laboratory or imaging studies beyond mammography in the absence of clinical signs or symptoms of recurrence. 1
The patient should also continue cardiac monitoring given trastuzumab exposure, with regular assessment recommended for at least 18 months from treatment initiation. 5